8-K: Celcuity Extends Deadline for $10 Million Loan Draw

Celcuity Inc. has amended its loan agreement to extend the deadline for drawing down a $10 million term loan to June 1, 2024.

Summary

• Celcuity Inc. has entered into a Second Amendment to its existing Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, L.P.
• This amendment extends the deadline for Celcuity to draw on a $10 million term loan (Term C Loan) from April 1, 2024, to June 1, 2024.
• The original loan agreement, dated April 8, 2021, provided for up to $75 million in funding through five term loans.
• The company previously drew $15 million on April 8, 2021, and an additional $20 million on December 22, 2022.
• The $10 million Term C Loan was contingent on achieving a specific milestone before April 1, 2024, which has now been extended to June 1, 2024.

Sentiment

Score: 7

Explanation: The document indicates a positive development with the extension of the loan draw period, providing the company with more flexibility. However, it also highlights the need to meet the conditions by the new deadline, which introduces some uncertainty.

Positives

• The extension of the Term C Draw Period provides Celcuity with additional flexibility and time to access the $10 million loan.
• The existing loan agreement remains in full force and effect, indicating continued support from Innovatus.

Risks

• The company must still meet the conditions for the Term C Loan by the new deadline of June 1, 2024.
• Failure to meet the conditions or draw the loan by the deadline could impact the company's financial position.

Future Outlook

The company has until June 1, 2024, to draw the $10 million Term C Loan, subject to meeting the conditions outlined in the Amended Loan Agreement.

Management Comments

• Brian F. Sullivan, Chief Executive Officer, signed the Second Amendment on behalf of Celcuity Inc.

Industry Context

This type of loan amendment is common in the biotech industry, where companies often rely on debt financing to fund research and development. Extending the draw period provides Celcuity with more time to achieve milestones and access capital.

Comparison to Industry Standards

• Many biotech companies utilize venture debt financing to support operations and development, similar to Celcuity's arrangement with Innovatus.
• The terms of the loan, including the total amount and the draw periods, are typical for companies at Celcuity's stage of development.
• Comparable companies often have similar loan agreements with milestones tied to clinical trial progress or other development goals.

Stakeholder Impact

• Shareholders may view the extension positively as it provides more time for the company to access capital.
• Creditors are likely to see the amendment as a continuation of the existing agreement.

Next Steps

• Celcuity needs to meet the conditions for the Term C Loan by June 1, 2024.
• The company will continue to operate under the terms of the Amended Loan Agreement.

Key Dates

Keywords

loan agreement, term loan, financing, debt, amendment, Celcuity, Innovatus, Term C Loan